Daxor Corporation announced new pilot randomized control trial (RCT) data from Duke Heart validating the greater accuracy of the Company's BVA-100 diagnostic in optimizing decongestion therapy for heart failure patients and pointed to a strong signal toward reducing hospital length of stay in a pilot cohort of 31 patients. Data were presented as a moderated featured abstract at the Technology Heart Failure Therapeutics Conference, which focuses on device and technology-based treatments in heart failure, held March 20-22, 2023 in Boston, Mass. Blood volume analysis (BVA) was used in hospitalized heart failure patients to study the effects of BVA-guided care on decongestion therapy and outcomes versus standard of care.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
9.765 USD | +3.88% | -4.08% | -2.08% |
Chiffre d''affaires - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-2.08% | 45.18M | |
+5.82% | 12.91B | |
+10.99% | 9.59B | |
+0.22% | 5.64B | |
+6.02% | 5.38B | |
+6.27% | 5.21B | |
+23.45% | 4.69B | |
+20.91% | 4.53B | |
+2.49% | 4.07B | |
+6.69% | 3.87B |
- Stock Market
- Equities
- DXR Stock
- News Daxor Corporation
- Daxor Corporation Announces Pilot Randomized Controlled Trial Validates Daxor BVA-100 Diagnostic for Heart Failure Patients